Interpace Diagnostics to Participate in 9th Annual Craig-Hallum Alpha Select Conference
November 09 2018 - 6:55AM
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today
that the Company has been invited to participate at the 9th Annual
Craig-Hallum Alpha Select Conference to be held on November 15,
2018 at the Sheraton New York Times Square Hotel. Companies, such
as Interpace, have been individually selected by the Craig-Hallum
research team based on several factors including above average
growth prospects, attractive business models, competitive
advantage, unappreciated value and strong management teams. The
Alpha Select List companies will be presented to top institutional
investors and analysts from across the country.
Interpace will host one-on-one meetings with
investors at the conference throughout the day. To schedule a
one-on-one meeting with management, please contact our
representatives at Edison Advisors or your Craig-Hallum
representative.
Conference Details:
Title: 9th Annual Craig-Hallum Alpha Select
ConferenceDate: Thursday, November 15,
2018Location: Sheraton New York Times Square
Hotel
811 7th
Avenue
New York, NY 10019
About Interpace Diagnostics Group, Inc.
Interpace is a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
diagnostic tests bioinformatics and pathology services for
evaluating risk of cancer by leveraging the latest technology in
personalized medicine for improved patient diagnosis and
management. The Company currently has four commercialized molecular
tests and one test in a clinical evaluation process (CEP);
PancraGEN for the diagnosis and prognosis of pancreatic cancer from
pancreatic cysts; ThyGenX® (now ThyGeNEXT™) for the diagnosis of
thyroid cancer from thyroid nodules utilizing a next generation
sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer
from thyroid nodules utilizing a proprietary gene expression assay;
and RespriDX™ that differentiates lung cancer of primary vs.
metastatic origin. BarreGEN® for Barrett's Esophagus, is currently
being “soft launched” with key opinion leaders as we continue to
gather data on this assay that will assist us in seeking favorable
reimbursement as well as important clinical information. Barrett's
Esophagus is a rapidly growing diagnosis that affects over three
million people in the US and over time can progress to esophageal
cancer. The Company’s data base includes data from over 45,000
patients who have been tested using the Company’s current products,
including over 25,000 molecular tests for thyroid nodules.
Interpace has been designated by the 2017 edition of CIO
Applications as one of the top 20 companies for providing
bioinformatics solutions. Interpace’s mission is to provide
personalized medicine through molecular diagnostics, innovation and
data to advance patient care based on rigorous science. For more
information, please visit Interpace’s website at
www.interpacediagnostics.com.
About Craig-Hallum Capital Group, LLC
Craig-Hallum is an employee-owned, idea-driven
research, trading and investment banking firm focused on emerging
growth companies and institutional investors. The firm provides
research, sales and trading for institutional investors, while the
investment banking group provides companies with financing
alternatives through initial public offerings, convertible
securities and private placements. For more information on the
Alpha Select Conference, please contact
chconference@craig-hallum.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from those
expressed or implied by any forward-looking statement. Known and
unknown risks, uncertainties and other factors include, but are not
limited to, the Company's ability to adequately finance the
business, its ability to restructure its liabilities and other
obligations, the market's acceptance of its molecular diagnostic
tests, its ability to retain or secure reimbursement, its ability
to secure additional business and generate higher profit margins
through sales of its molecular diagnostic tests, in-licensing or
other means, projections of future revenues, growth, gross profit
and anticipated internal rate of return on investments and its
ability to maintain its NASDAQ listing.. Additionally, all
forward-looking statements are subject to the “Risk Factors”
detailed from time to time in the Company's most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS:Interpace DiagnosticsEdison Advisors - Investor
RelationsJoseph Green (646) 653 – 7030 jgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024